Table 1.

Summary of long-acting rhGH preparations

Class	Company	Product	Design	Status
Depot Formulations
	Genentech / Alkermes	Nutropin Depot	Encapsulated in Polylactide-Coglycolide Microspheres	FDA Approved. Removed from market in 2004.
	BioPartners / LG Life Sciences	Declage LB03002	rhGH incorporated into sodum hyaluronate and suspended in MCT for injection	Available for use by children in South Korea. Approved in Europe but not marketed.
PEGylated Formulations
	Ambrx	ARX201	30-kDa PEG incorporated into rhGH	Drug development stopped due to PEG accumulation in ependymal cells of choroid plexus.
	Novo Nordisk	NNCI126–0083	43-kDa PEG attached to rhGH	Drug development stopped.
	Pfizer	PHA-794428	Branched 40-kDa PEG attached to amino end of GH	Drug development stopped.
	GeneScience Pharmaceuticals	Jintrolong	40-kDa PEG attached to rhGH	Available for use by children in China.
Pro-drug Formulations
	Ascendis Pharma	TransCon Growth Hormone	rhGH transiently bound to mPEG	In phase 3 testing.
Non-Covalent Albumin Binding GH
	Novo Nordisk	Somapacitan NNC0195–0092	rhGH with a single po int mutation attached to a terminal fatty acid	In phase 3 testing.
GH Fusion Proteins
	Genexine / Handok	HyTropin GX-H9	rhGH fused to IgD and IgG4	Pending phase 3 testing.
	Teva	TV-1106	rhGH fused to albumin	Blocking/inactivating antibodies developed, drug abandoned.
	OPKO Health / Pfizer	MOD-4023	rhGH fused to 3 copies of carboxy-terminal of hCG’s beta subunit	Phase 3 studies in adults completed at end of 2016, phase 3 testing in children underway.
	Versartis	Somavaratan VRS-317	rhGH fused to hydrophilic strings of amino acids	Discontinued due to inferiority to daily rhGH in increasing height in children